Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines

scientific article published on 8 October 2017

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1155/2017/7694202
P932PMC publication ID5651099
P698PubMed publication ID29119113

P50authorKaterina PolitiQ66809333
Fred R HirschQ89864676
Kenichi SudaQ42316056
P2093author name stringHui Yu
Tetsuya Mitsudomi
Koh Furugaki
Christopher J Rivard
Kim Ellison
Leslie Rozeboom
Mary Ann C Melnick
P2860cites workCheckpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.Q51372253
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.Q54339119
Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysisQ79209903
Subsets of epidermal growth factor receptors during activation and endocytosisQ24317697
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.Q33819404
Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancerQ36801144
Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destinyQ38021967
Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.Q38486882
Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cellsQ38746756
PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung CancerQ38804050
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A ReviewQ38867118
EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB.Q38872276
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR MutationQ38912283
New and emerging targeted treatments in advanced non-small-cell lung cancer.Q38947183
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerQ38975751
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumorsQ39089944
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison ProjectQ39135152
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialQ40163779
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung CancerQ40241719
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.Q41112103
Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptorQ42807646
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancerQ42815191
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.Q48020812
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P4510describes a project that usesImageQuantQ112270642
P407language of work or nameEnglishQ1860
P304page(s)7694202
P577publication date2017-10-08
P1433published inBioMed Research InternationalQ17509958
P1476titleIncreased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines
P478volume2017

Reverse relations

cites work (P2860)
Q91937343Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
Q97537416Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?
Q92942818MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Q98291341PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR

Search more.